Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hannes Wandt

Showing results (1-10 of 35) with videos related to

Pageof 4
Sort By:
Lancet (London, England)|March 12, 2013
Therapeutic platelet transfusion for hypoproliferative thrombocytopenia - authors' replyHannes Wandt, Kerstin Schaefer-Eckart
Deutsches Arzteblatt International|August 8, 2015
In ReplyHannes Wandt, Kerstin Schäfer-Eckart, Andreas Greinacher
The New England Journal of Medicine|August 9, 2013
Prophylactic platelet transfusionHannes Wandt, Kerstin Schäfer-Eckart, Gerhard Ehninger
Haematologica|September 13, 2005
Two allogeneic hematopoietic stem cell transplantations without the use of blood-product supportHannes Wandt, Kerstin Schaefer-Eckart, Martin Wilhelm
Deutsches Arzteblatt International|December 17, 2014
Platelet transfusion in hematology, oncology and surgeryHannes Wandt, Kerstin Schäfer-Eckart, Andreas Greinacher
Blood|January 23, 2010
WHO classification of myeloid neoplasms and leukemiaHannes Wandt, Torsten Haferlach, Christian Thiede, et al.
Clinical Nuclear Medicine|September 16, 2003
FDG PET for imaging pericardial manifestations of Hodgkin lymphomaInga Buchmann, Hannes Wandt, Andreas Wahl, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 9, 2010
Long-term follow-up of an intensified myeloablative conditioning regimen with in vivo T cell depletion followed by allografting in patients with advanced multiple myelomaNicolaus Kröger, Hermann Einsele, Günter Derigs, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2007
Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMTVolker Möbus, Hannes Wandt, Norbert Frickhofen, et al.
Cancer|August 1, 2006
Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study GroupChristina Nickenig, Martin Dreyling, Eva Hoster, et al.
Pageof 4

Showing results (1-10 of 35) with videos related to

Sort By:
Pageof 4
Lancet (London, England)|March 12, 2013
Therapeutic platelet transfusion for hypoproliferative thrombocytopenia - authors' replyHannes Wandt, Kerstin Schaefer-Eckart
Deutsches Arzteblatt International|August 8, 2015
In ReplyHannes Wandt, Kerstin Schäfer-Eckart, Andreas Greinacher
The New England Journal of Medicine|August 9, 2013
Prophylactic platelet transfusionHannes Wandt, Kerstin Schäfer-Eckart, Gerhard Ehninger
Haematologica|September 13, 2005
Two allogeneic hematopoietic stem cell transplantations without the use of blood-product supportHannes Wandt, Kerstin Schaefer-Eckart, Martin Wilhelm
Deutsches Arzteblatt International|December 17, 2014
Platelet transfusion in hematology, oncology and surgeryHannes Wandt, Kerstin Schäfer-Eckart, Andreas Greinacher
Blood|January 23, 2010
WHO classification of myeloid neoplasms and leukemiaHannes Wandt, Torsten Haferlach, Christian Thiede, et al.
Clinical Nuclear Medicine|September 16, 2003
FDG PET for imaging pericardial manifestations of Hodgkin lymphomaInga Buchmann, Hannes Wandt, Andreas Wahl, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 9, 2010
Long-term follow-up of an intensified myeloablative conditioning regimen with in vivo T cell depletion followed by allografting in patients with advanced multiple myelomaNicolaus Kröger, Hermann Einsele, Günter Derigs, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2007
Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMTVolker Möbus, Hannes Wandt, Norbert Frickhofen, et al.
Cancer|August 1, 2006
Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study GroupChristina Nickenig, Martin Dreyling, Eva Hoster, et al.
Pageof 4